Ibuprofen 600 mg tablets recalled for failed tablet specifications
Dr. Reddy's Laboratories is recalling ibuprofen 600 mg tablets for failed tablet specifications. The affected product was distributed nationwide.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: This is an FDA Class III recall with no reported illnesses or injuries. FDA Class III recalls address situations not likely to cause adverse health consequences. No specific hazard or documented harm has been articulated in the recall notice.
Plain-English summary
Dr. Reddy's Laboratories, Inc. is recalling IBU (ibuprofen) 600 mg tablets in 500-count bottles because the product failed tablet specifications. The recalled lot is C5406201 with an expiration date of 03/31/2028 and was distributed nationwide in the United States.
The FDA has classified this as a Class III recall. Consumers who have purchased this product should consult their healthcare provider or pharmacist before continuing use. Do not use any remaining tablets from the recalled lot and follow your healthcare provider's guidance on safe disposal or return of the product.
The recalled product
- Product
- IBU (IBUPROFEN)
- Brand
- IBU
- Manufacturer
- Dr. Reddy's Laboratories, Inc.
- Category
- Drug — Prescription Ibuprofen
- Hazard
- specification-failure
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: C5406201
- Exp 03/31/2028
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · IBU
- HighPrescription Ibuprofen Recalled Due to Failed Impurity Specifications
FDA (Drugs) · 2024-09-04
- HighPrescription Ibuprofen Tablets Recalled for Excessive Unknown Impurities
FDA (Drugs) · 2024-09-04
- HighIBU Prescription Ibuprofen Tablets Recalled for Failed Impurity Specifications
FDA (Drugs) · 2024-09-04
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27